Post-prandial lipid levels for assessing target goal achievement in type 2 diabetic patients taking statin

Journal of Korean Medical Science

Volumn 25, Issue 3, 2010, Pages 387-392

  Kim, Mikyung ^a,c   Suk, Jihye ^a   Kim, Hyunjung ^a   Jung, Hyesuk ^c   Kim, Taeik ^a   Park, Jeonghyun ^b,c  

^a Maryknoll Hospital   (South Korea)

^b Inje University College of Medicine   (South Korea)

^c Inje University   (South Korea)

Author keywords

Diabetes mellitus; Fasting; Korean diet; Lipid goal; Postprandial period; Type 2

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

AGED; ARTICLE; BLOOD; DIET; DIET RESTRICTION; FEMALE; HUMAN; KOREA; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE; PREGNANCY;

AGED; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; DIET; FASTING; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KOREA; MALE; MIDDLE AGED; POSTPRANDIAL PERIOD; PREGNANCY;

EID: 77952315241     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2010.25.3.387     Document Type: Article

References (26)

1. American Diabetes Association. Standards of medical care in diabetes-2008. Diabetes Care 2008; 31 (Suppl 1): S12-54.
2. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP). Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97.
3. Bottorff MB. Underidentification and undertreatment issues. J Manag Care Pharm 2003; 9: 6-8.
4. Kolding Kristensen J, Lauritzen T. Inadequate treatment of dyslipidemia in people with type 2 diabetes: quality assessment of diabetes care in a Danish County. Scand J Prim Health Care 2006; 24: 181-5.
5. Primatesta P, Poulter NR. Levels of dyslipidemia and improvement in its management in England: results from the Health Survey for England 2003. Clin Endocrinol (Oxf) 2006; 64: 292-8.
6. Weiss R, Harder M, Rowe J. The relationship between nonfasting and fasting lipid measurements in patients with or without type 2 diabetes mellitus receiving treatment with 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. Clin Ther 2003; 25: 1490-7.
7. Schaefer EJ, Audelin MC, McNamara JR, Shah PK, Tayler T, Daly JA, Augustin JL, Seman LJ, Rubenstein JJ. Comparison of fasting and postprandial plasma lipoproteins in subjects with and without coronary heart disease. Am J Cardiol 2001; 88: 1129-33.
8. Schaefer EJ, McNamara JR, Tayler T, Daly JA, Gleason JA, Seman LJ, Ferrari A, Rubenstein JJ. Effects of atorvastatin on fasting and postprandial lipoprotein subclasses in coronary heart disease patients versus control subjects. Am J Cardiol 2002; 90: 689-96.
9. Wilder LB, Bachorik PS, Finney CA, Moy TF, Becker DM. The effect of fasting status on the determination of low-density and high-density lipoprotein cholesterol. Am J Med 1995; 99: 374-7.
10. Dungan KM, Guster T, DeWalt DA, Buse JB. A comparison of lipid and lipoprotein measurements in the fasting and nonfasting states in patients with type 2 diabetes. Curr Med Res Opin 2007; 23: 2689-95.
11. Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screeners of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 1986; 256: 2823-8.
12. The Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9.
13. Shepherd J. Preventing coronary artery disease in the West of Scotland: implications for primary prevention. Am J Cardiol 1998; 82: 57-9.
14. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002; 360: 7-22.
15. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, Ebrahim S, Faergeman O, Graham I, Mancia G, Cats VM, Orth-Gomér K, Perk J, Pyörälä K, Rodicio JL, Sans S, Sansoy V, Sechtem U, Silber S, Thomsen T, Wood D; European Society of Cardiology Committee for Practice Guidelines. European guidelines on cardiovascular disease prevention in clinical practice: executive summary of the Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur J Cardiovasc Prev Rehabil 2003; 10: S1-10.
16. EUROASPIRE I and II Group. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. European Action on Secondary Prevention by Intervention to Reduce Events. Lancet 2001; 357: 995-1001.
17. Pearson TA, Laurora I, Chu H. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dys-lipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000; 160: 459-67.
18. Frolkis JP, Zyzanski SJ, Schwartz JM, Suhan PS. Physician non-compliance with the 1993 National Cholesterol Education Program (NCEP-ATPII) guidelines. Circulation 1998; 98: 851-5.
19. Van Ganse E, Laforest L, Alemao E, Davies G, Gutkin S, Yin D. Lipid-modifying therapy and attainment of cholesterol goals in Europe: the Return on Expenditure Achieved for Lipid Therapy (REALITY) study. Curr Med Res Opin 2005; 21: 1389-99.
20. Euro Heart Survey Programme. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II. Eur Heart J 2001; 22: 554-72.
21. Dubois C, Beaumier G, Juhel C, Armand M, Portugal H, Pauli AM, Borel P, Latge C, Lairon D. Effects of graded amounts (0-50 g) of dietary fat on postprandial lipemia and lipoproteins in normolipidemic adults. Am J Clin Nutr 1998; 67: 31-8.
22. Williams PT, Blanche PJ, Rawlings R, Krauss RM. Concordant lipoprotein and weight responses to dietary fat change in identical twins with divergent exercise levels 1. Am J Clin Nutr 2005; 82: 181-7.
23. Hayek T, Ito Y, Azrolan N, Verdery RB, Aalto-Setälä K, Walsh A, Breslow JL. Dietary fat increases high density lipoprotein (HDL) levels both by increasing the transport rates and decreasing fractional catabolic rates of HDL cholesterol ester and apolipoprotein (apo) A-I. Presentation of a new animal model and mechanistic studies in human Apo A-I transgenic and control mice. J Clin Invest 1993; 91: 1665-71.
24. Volek JS, Sharman MJ, Gómez AL, DiPasquale C, Roti M, Pumerantz A, Kraemer WJ. Comparison of a very low-carbohydrate and low-fat diet on fasting lipids, LDL subclasses, insulin resistance, and postprandial lipemic responses in overweight women. J Am Coll Nutr 2004; 23: 177-84.
25. Hegsted DM, Kritchevsky D. Diet and serum lipid concentrations: where are we? Am J Clin Nutr 1997; 65: 1893-6.
26. Lund SS, Tarnow L, Frandsen M, Smidt UM, Pedersen O, Parving HH, Vaag AA. Impact of metformin versus the prandial insulin secretagogue, repaglinide, on fasting and postprandial glucose and lipid responses in non-obese patients with type 2 diabetes. Eur J Endocrinol 2008; 158: 35-46.